Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer.

Daijiro HaradaAtsushi ShimonishiKazuhiko SaekiTakashi NinomiyaHiromitsu KanzakiKei NagasakiChina OguraYoko TsutsuiKazuhiro KojinYasushi HamamotoToshiyuki Kozuki

Published in: Asia-Pacific journal of clinical oncology (2022)

The initiation of Durva therapy within 14 days after TRT may increase the risk of pneumonitis grade 2 or above. Careful observation and suitable treatment are recommended.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
rectal cancer
interstitial lung disease
locally advanced
stem cells
squamous cell carcinoma
mesenchymal stem cells
tyrosine kinase
cell therapy
idiopathic pulmonary fibrosis
smoking cessation